首页> 外文期刊>Indian Journal of Experimental Biology >Prolonged release biodegradable vesicular carriers for rifampicin—Formulation and kinetics of release
【24h】

Prolonged release biodegradable vesicular carriers for rifampicin—Formulation and kinetics of release

机译:利福平缓释生物可降解囊泡载体的释放和释放动力学

获取原文
获取原文并翻译 | 示例
       

摘要

An attempt has been made to design suitable liposome and niosome-encapsulated drug delivery system for rifampicin and evaluated the same in vitro and in vivo. A modified lipid layer hydration method was employed to prepare these vesicular carriers. The formulated systems were characterized in vitro for size distribution analysis, drug entrapment, drug release profiles and vesicular stability at different conditions of storage. In vivo drug kinetics was evaluated in normal, healthy albino rats for niosomal formulation upon subcutaneous injection and various pharmacokinetic parameters were determined. Niosomes and liposomes exhibited mean diameter of 9.73 and 11.87 μm with entrapment efficiencies of 30.5 and 34.2% respectively. Both the products exhibited sustained release characteristics in vitro with zero order drug release kinetics up to initial 10 hr. Stability evaluation indicated that both formulations were not significantly leaky over a period of one month. Niosomal formulation elevated plasma elimination half life and decreased elimination rate constants for rifampicin in vivo suggested that encapsulation retarded the removal of the drug from circulation compared to free drug due to slow drug release into systemic circulation. A five-fold increase in the area under plasma rifampicin concentration-time curve for niosomal rifampicin as compared to free drug indicated better bioavailability of encapsulated drug. It is evident from this study that niosomes and liposomes could be promising delivery systems for rifampicin with prolonged drug release profiles and reasonably good stability characteristics.
机译:已经尝试设计用于利福平的合适的脂质体和脂质体包裹的药物递送系统,并在体外和体内对其进行了评估。采用改良的脂质层水合方法制备这些囊泡载体。对配制的系统进行体外表征,以在不同的储存条件下进行大小分布分析,药物截留,药物释放曲线和囊泡稳定性。皮下注射后,在正常,健康的白化病大鼠中评估了血浆制剂的体内药物动力学,并确定了各种药代动力学参数。脂质体和脂质体的平均直径分别为9.73和11.87μm,包封率分别为30.5%和34.2%。两种产品均在体外表现出持续释放特性,在最初的10小时内具有零级药物释放动力学。稳定性评估表明,两种配方在一个月的时间内均没有明显泄漏。 Niosomal制剂提高了体内血浆利福平的血浆消除半衰期,降低了消除速率常数,这表明与游离药物相比,由于药物缓慢释放至全身循环,与自由药物相比,包囊阻碍了药物从循环中的去除。与游离药物相比,血浆利福平在血浆利福平浓度-时间曲线下的面积增加了五倍,表明封装的药物具有更好的生物利用度。从这项研究中可以明显看出,脂质体和脂质体可能是利福平的有前途的递送系统,具有延长的药物释放曲线和相当好的稳定性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号